Literature DB >> 2845248

DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition.

K C Chow1, T L Macdonald, W E Ross.   

Abstract

Previous evidence suggests that epipodophyllotoxins, such as etoposide and teniposide, and the N-acyl anthracycline AD41 inhibit topoisomerase II resealing even though they apparently do not bind to DNA. Using experimental conditions designed to detect limited numbers of DNA binding sites, we now report that both epipodophyllotoxins and the N-acyl anthracyclines AD41 and AD32 bind to DNA. Binding was greater to kinetoplast DNA than to pUC18 plasmid DNA. There was also greater etoposide binding to single-stranded DNA than to double-stranded linear or supercoiled DNA. Based on binding competition experiments, etoposide and teniposide appear to have equal affinity for DNA, in spite of the fact that the latter is more potent as a topoisomerase inhibitor. This suggests that the difference in the drugs relates to protein interaction. There are 3- to 7-fold more binding sites for AD41 than for AD32, depending on the DNA substrate employed, and both drugs, unlike adriamycin, exhibit saturation of binding sites over a concentration range of 0-50 microM when kinetoplast DNA is the substrate. Evidence for DNA intercalation by AD41 is provided by the observation that the drug introduces positive supercoils into covalently closed plasmid DNA. Based on these data, a hypothesis is proposed that would provide a general mechanism whereby intercalating agents and epipodophyllotoxins alter topoisomerase function and presumably exert their antitumor effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845248

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I.

Authors:  Arnab Roy Chowdhury; Shalini Sharma; Suparna Mandal; Anindya Goswami; Sibabrata Mukhopadhyay; Hemanta K Majumder
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

2.  The recognition of DNA cleavage sites by porcine spleen topoisomerase II.

Authors:  H W Huang; J K Juang; H J Liu
Journal:  Nucleic Acids Res       Date:  1992-02-11       Impact factor: 16.971

3.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

4.  The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Biochemistry       Date:  2006-03-07       Impact factor: 3.162

5.  Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Authors:  Y Pommier; G Capranico; A Orr; K W Kohn
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

Review 6.  Valrubicin.

Authors:  S V Onrust; H M Lamb
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

7.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.

Authors:  Amanda C Gentry; Steven L Pitts; Michael J Jablonsky; Christian Bailly; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2011-03-28       Impact factor: 3.162

8.  Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.

Authors:  Ryan P Bender; Michael J Jablonksy; Mohammad Shadid; Ian Romaine; Norma Dunlap; Clemens Anklin; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2008-03-21       Impact factor: 3.162

9.  Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent.

Authors:  Sunil Shah; Rahul Chib; Sangram Raut; Jaclyn Bermudez; Nirupama Sabnis; Divya Duggal; Joseph D Kimball; Andras G Lacko; Zygmunt Gryczynski; Ignacy Gryczynski
Journal:  J Photochem Photobiol B       Date:  2015-12-18       Impact factor: 6.252

10.  The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Authors:  Brian B Hasinoff; Xing Wu; John L Nitiss; Ragu Kanagasabai; Jack C Yalowich
Journal:  Biochem Pharmacol       Date:  2012-10-05       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.